Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2020 Jul 6;16(2):437–453. doi: 10.1007/s11481-020-09936-5

Figure 8. RNA expression of CD11b and GFAP in the CNS of immunocompetent vs. immunocompromised gp120tg mice.

Figure 8.

Young (8-10 week old) and old (4-5 months old) gp120tg+ and gp120tg− mice were euthanized at 12 weeks post-LP-BM5 treatment (5x104 pfu, i.p.). RNA expression of CD11b (A-C) and GFAP (D-F) in the hippocampus (A and D), frontal lobe (B and E), and striatum (C and F) are shown in interaction plots. Data are presented as mean ± SEM; n=7-16/group. Two-way ANOVA followed by Tukey post hoc test were performed. # p<0.05 between the indicated groups regardless of LP-BM5 treatment. $p<0.05 between indicated groups under LP-BM5 treatment condition only.